Search clinical trials for: PF-06651600 Placebo

Total 54826 results

Pfizer

Terminated

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

Healthy Elderly

United States
Pfizer

Completed

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

Healthy

United States
Pfizer

Completed

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Narcolepsy | Excessive Daytime Sleepiness

United States
Pfizer

Completed

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Hepatitis C

Belgium, Germany, United Kingdom
Pfizer

Completed

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study To Evaluate PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
University of Pennsylvania
Pfizer

Completed

Add On Treatment for Cognitive Deficits in Schizophrenia

Schizophrenia

United States
Pfizer

Completed

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

Healthy

United States
Pfizer
Bristol-Myers Squibb

Completed

A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects

Healthy

Singapore, Belgium
Pfizer

Completed

Multiple Dose Healthy Volunteer Study of PF-03715455. (MD-MULTI DOSE)

Healthy Volunteers

Singapore
Taisho Pharmaceutical Co., Ltd.

Completed

A Study Of The Effect Of PF-04802540 On Sleep Measures

Healthy

United States
Pfizer

Completed

A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects

Pain

Belgium
Pfizer

Completed

A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects

Healthy

Singapore
Pfizer

Completed

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

Bipolar Depression

United States
Pfizer

Completed

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Overweight

United States
Pfizer

Terminated

Topical Multiple Ascending Dose Study for PF-06423264

Normal Healthy

Belgium
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

Healthy Volunteers

United States
Pfizer

Active, not recruiting

A Study to Learn How Different Amounts and Forms of the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults

Healthy Participants

Belgium
Pfizer

Active, not recruiting

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States, Poland, Germany
Pfizer

Completed

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Healthy Participants

Belgium
Pfizer

Completed

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

SARS-CoV-2 Infection

United States
Pfizer

Completed

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Rheumatoid Arthritis | Systemic Lupus Erythematosus

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Yale University

Completed

Cannabinoid Augmentation of Fear Response in Humans

Fear Conditioning

United States
Pfizer

Terminated

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

Healthy

Belgium
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Pfizer

Completed

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Hypertension

United States
Biogen

Completed

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Healthy

Japan
Pfizer

Completed

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects

Healthy

Japan
Pfizer

Completed

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Normal Healthy

United States
Pfizer

Completed

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512

Healthy

Belgium
Pfizer

Terminated

Safety and Tolerability of PF-06818883 in Healthy Subjects

Healthy

United States
Pfizer

Completed

First in Human Study for PF-06667272

Healthy

Belgium
Pfizer

Terminated

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Healthy

United States
Pfizer

Completed

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Diabetic Nephropathy

United States, Spain, Korea, Republic of, Australia, Hong Kong, Germany, Poland, Italy, Canada, Puerto Rico, Malaysia, Romania, Argentina, Peru

3

Subscribe